Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The
available therapy is limited to the symptomatic treatment and its efficacy remains …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by decreased
synaptic transmission and cerebral atrophy with appearance of amyloid plaques and …

The endocannabinoid system (ECS) exerts a modulatory effect of important functions such
as neurotransmission, glial activation, oxidative stress, or protein homeostasis …

We present the synthesis and characterization of merged human butyrylcholinesterase (h
BChE) inhibitor/cannabinoid receptor 2 (h CB2R) ligands for the treatment of …

Alzheimer's disease (AD) is a progressive multifactorial neurodegenerative disorder.
Currently, no effective treatment is available and this is due to multiple factors involved in …

The complex pathogenesis of Alzheimer's disease (AD) calls for multitarget approach for
disease management. Herein, a series of novel flurbiprofen-chalcone hybrid Mannich base …

The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic
target for its involvement in the first steps of neurodegeneration as well as in cancer onset …

The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (h CB2R)
represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease …

Background: Neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic
lateral sclerosis, Parkinson's disease (PD), spinal cerebellar ataxias, and spinal and bulbar …

A series of rivastigmine-caffeic acid and rivastigmine-ferulic acid hybrids were designed,
synthesized, and evaluated as multifunctional agents for Alzheimer's disease (AD) in vitro …